Joanna Bao-Ern Loh, Cameron Wellard, Helen E Haysom, Rosemary L Sparrow, Erica M Wood, Zoe K McQuilten
{"title":"大量输血接受者给予abo血型不相容的新鲜冷冻血浆的结果。","authors":"Joanna Bao-Ern Loh, Cameron Wellard, Helen E Haysom, Rosemary L Sparrow, Erica M Wood, Zoe K McQuilten","doi":"10.1111/trf.18070","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The provision of ABO-incompatible fresh frozen plasma (FFP) in massive transfusion (MT) has become accepted to conserve AB FFP stock. There is an evidence gap in non-trauma settings. We compare characteristics of patients who received ABO-compatible or ABO-incompatible FFP during an MT episode due to any cause of critical bleeding, and assess the impact of incompatible FFP transfusion on inhospital mortality.</p><p><strong>Methods: </strong>Using the Australian and New Zealand Massive Transfusion Registry, data were extracted for patients aged ≥18 years who received an MT (defined as ≥5 red cell units in 4 h) between April 2011 and October 2018. Incompatible FFP was defined as transfusion of ≥1 unit of FFP with a bidirectional or minor ABO-mismatch in the first 24 h from MT initiation.</p><p><strong>Results: </strong>A total of 7340 patients from 28 hospitals were included. Seventy-seven (1%) patients received incompatible FFP (26 trauma, 51 non-trauma). Those who had incompatible FFP received a median of seven units of FFP, compared to those who only received compatible FFP receiving five units, p = .005. A total of 226 units of incompatible FFP were provided overall. Incompatible FFP provision was not independently associated with inhospital mortality in MT (HR of 1.40 [95% CI 0.84-2.26, p = .2]). Variables independently associated with inhospital mortality included increased FFP volume in the first 24 h, age, Charlson Comorbidity Index score, and lower pre-transfusion fibrinogen and peri-transfusion pH values.</p><p><strong>Conclusion: </strong>Transfusion of incompatible FFP in MT in our cohort was not independently associated with higher inhospital mortality, although the number of patients who received incompatible FFP was small.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":"58-72"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcomes of massive transfusion recipients administered ABO-incompatible fresh frozen plasma.\",\"authors\":\"Joanna Bao-Ern Loh, Cameron Wellard, Helen E Haysom, Rosemary L Sparrow, Erica M Wood, Zoe K McQuilten\",\"doi\":\"10.1111/trf.18070\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The provision of ABO-incompatible fresh frozen plasma (FFP) in massive transfusion (MT) has become accepted to conserve AB FFP stock. There is an evidence gap in non-trauma settings. We compare characteristics of patients who received ABO-compatible or ABO-incompatible FFP during an MT episode due to any cause of critical bleeding, and assess the impact of incompatible FFP transfusion on inhospital mortality.</p><p><strong>Methods: </strong>Using the Australian and New Zealand Massive Transfusion Registry, data were extracted for patients aged ≥18 years who received an MT (defined as ≥5 red cell units in 4 h) between April 2011 and October 2018. Incompatible FFP was defined as transfusion of ≥1 unit of FFP with a bidirectional or minor ABO-mismatch in the first 24 h from MT initiation.</p><p><strong>Results: </strong>A total of 7340 patients from 28 hospitals were included. Seventy-seven (1%) patients received incompatible FFP (26 trauma, 51 non-trauma). Those who had incompatible FFP received a median of seven units of FFP, compared to those who only received compatible FFP receiving five units, p = .005. A total of 226 units of incompatible FFP were provided overall. Incompatible FFP provision was not independently associated with inhospital mortality in MT (HR of 1.40 [95% CI 0.84-2.26, p = .2]). Variables independently associated with inhospital mortality included increased FFP volume in the first 24 h, age, Charlson Comorbidity Index score, and lower pre-transfusion fibrinogen and peri-transfusion pH values.</p><p><strong>Conclusion: </strong>Transfusion of incompatible FFP in MT in our cohort was not independently associated with higher inhospital mortality, although the number of patients who received incompatible FFP was small.</p>\",\"PeriodicalId\":23266,\"journal\":{\"name\":\"Transfusion\",\"volume\":\" \",\"pages\":\"58-72\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Transfusion\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/trf.18070\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/31 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/trf.18070","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/31 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:在大量输血(MT)中提供abo血型不相容的新鲜冷冻血浆(FFP)已被接受用于保存AB血型的FFP储备。在非创伤环境中存在证据缺口。我们比较了因任何原因导致严重出血而在MT发作期间接受abo相容或abo不相容FFP的患者的特征,并评估不相容FFP输血对住院死亡率的影响。方法:使用澳大利亚和新西兰大规模输血登记处,提取2011年4月至2018年10月期间接受MT(定义为4小时内≥5个红细胞单位)的≥18岁患者的数据。不相容的FFP被定义为在MT开始后的前24小时内输入≥1单位的FFP,且双向或轻微的abo -不匹配。结果:共纳入28家医院7340例患者。77例(1%)患者接受了不相容的FFP治疗(26例创伤,51例非创伤)。那些有不相容FFP的患者接受了中位数7单位的FFP,而那些只接受相容FFP的患者接受了5单位的FFP, p = 0.005。共提供不相容FFP 226个单位。不相容的FFP供应与MT患者住院死亡率没有独立关联(相对危险度为1.40 [95% CI 0.84-2.26, p = 0.2])。与住院死亡率独立相关的变量包括前24小时FFP体积增加、年龄、Charlson合并症指数评分、输血前纤维蛋白原和输血前后pH值降低。结论:在我们的队列中,MT患者输注不相容的FFP与较高的住院死亡率没有独立关联,尽管接受不相容FFP的患者数量很少。
Outcomes of massive transfusion recipients administered ABO-incompatible fresh frozen plasma.
Background: The provision of ABO-incompatible fresh frozen plasma (FFP) in massive transfusion (MT) has become accepted to conserve AB FFP stock. There is an evidence gap in non-trauma settings. We compare characteristics of patients who received ABO-compatible or ABO-incompatible FFP during an MT episode due to any cause of critical bleeding, and assess the impact of incompatible FFP transfusion on inhospital mortality.
Methods: Using the Australian and New Zealand Massive Transfusion Registry, data were extracted for patients aged ≥18 years who received an MT (defined as ≥5 red cell units in 4 h) between April 2011 and October 2018. Incompatible FFP was defined as transfusion of ≥1 unit of FFP with a bidirectional or minor ABO-mismatch in the first 24 h from MT initiation.
Results: A total of 7340 patients from 28 hospitals were included. Seventy-seven (1%) patients received incompatible FFP (26 trauma, 51 non-trauma). Those who had incompatible FFP received a median of seven units of FFP, compared to those who only received compatible FFP receiving five units, p = .005. A total of 226 units of incompatible FFP were provided overall. Incompatible FFP provision was not independently associated with inhospital mortality in MT (HR of 1.40 [95% CI 0.84-2.26, p = .2]). Variables independently associated with inhospital mortality included increased FFP volume in the first 24 h, age, Charlson Comorbidity Index score, and lower pre-transfusion fibrinogen and peri-transfusion pH values.
Conclusion: Transfusion of incompatible FFP in MT in our cohort was not independently associated with higher inhospital mortality, although the number of patients who received incompatible FFP was small.
期刊介绍:
TRANSFUSION is the foremost publication in the world for new information regarding transfusion medicine. Written by and for members of AABB and other health-care workers, TRANSFUSION reports on the latest technical advances, discusses opposing viewpoints regarding controversial issues, and presents key conference proceedings. In addition to blood banking and transfusion medicine topics, TRANSFUSION presents submissions concerning patient blood management, tissue transplantation and hematopoietic, cellular, and gene therapies.